PAaM用于肝硬化患者肝细胞癌风险分层的3期验证
研究将分子(预后肝脏分泌组特征联合甲胎蛋白)与临床(aMAP评分)变量整合为PAaM,在德州肝癌联盟和全国肝癌早期检测策略两个前瞻性队列中按前瞻性标本采集、回顾性盲法评估设计进行3期验证。PAaM将肝硬化患者分为高、中、低危三组,各组年肝癌发生率呈梯度上升,高危和中危组较低于低危组的亚分布风险比在兩個队列中均显著升高,且在包括代谢功能障碍相关脂肪性肝病和治愈丙型肝炎感染在内的不同病因中分层稳健。
要点
- PAaM整合分子与临床变量,在肝硬化人群中实现肝癌风险分层。
- 德州队列高、中、低危组年肝癌发生率分别为5.3%、2.7%、0.6%。
- 早期检测队列高、中危组较低危组的亚分布风险比分别为6.54和1.77。
核心结论
- PAaM能够对当代病因的肝硬化患者进行准确的肝癌风险分层。
研究设计与样本
- 研究为3期生物标志物验证研究,采用前瞻性标本采集、回顾性盲法评估设计。
- 验证队列包括德州肝癌联盟(2156例肝硬化患者)和全国肝癌早期检测策略前瞻性队列(1328例肝硬化患者)。
- 基线PAaM与 incident HCC 的关联采用Fine-Gray回归评估,以全因死亡和肝移植为竞争事件。
主要发现
- 德州肝癌联盟队列中,PAaM识别高危404例(19%)、中危903例(42%)、低危849例(39%),年肝癌发生率分别为5.3%、2.7%、0.6%。
- 德州队列中,高危组和中危组较低危组的亚分布风险比分别为7.51(95% CI,4.42-12.8)和4.20(95% CI,2.52-7.01)。
- 早期检测队列中,PAaM识别高危201例(15%)、中危540例(41%)、低危587例(44%),年肝癌发生率分别为6.2%、1.8%、0.8%。
- 早期检测队列中,高危组和中危组较低危组的亚分布风险比分别为6.54(95% CI,3.85-11.1)和1.77(95% CI,1.02-3.08)。
- 亚组分析显示,在包括代谢功能障碍相关脂肪性肝病和治愈丙型肝炎感染在内的不同肝癌病因中,风险分层均稳健。
关键数值与推荐
- PAaM由预后肝脏分泌组特征联合甲胎蛋白与aMAP评分(年龄、男性、白蛋白-胆红素、血小板)整合而成。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) risk stratification is an urgent unmet need for cost-effective HCC screening and early detection in patients with cirrhosis to improve poor HCC prognosis. METHODS: Molecular (prognostic liver secretome signature with α-fetoprotein) and clinical (aMAP [age, male sex, albumin-bilirubin, and platelets] score) variable-based scores were integrated into PAaM (prognostic liver secretome signature with α-fetoprotein plus age, male sex, albumin-bilirubin, and platelets), which was subsequently validated in 2 phase 3 biomarker validation studies: the statewide Texas HCC Consortium and nationwide HCC Early Detection Strategy prospective cohorts, following the prospective specimen collection, retrospective blinded evaluation design. The associations between baseline PAaM and incident HCC were assessed using Fine-Gray regression, with overall death and liver transplantation as competing events. RESULTS: Of 2156 patients with cirrhosis in the Texas HCC Consortium, PAaM identified 404 (19%) high-risk, 903 (42%) intermediate-risk, and 849 (39%) low-risk patients with annual HCC incidence rates of 5.3%, 2.7%, and 0.6%, respectively. Compared with low-risk patients, high- and intermediate-risk groups had sub-distribution hazard ratios for incident HCC of 7.51 (95% CI, 4.42-12.8) and 4.20 (95% CI, 2.52-7.01), respectively. Of 1328 patients with cirrhosis in the HCC early detection strategy, PAaM identified 201 high-risk (15%), 540 intermediate-risk (41%), and 587 low-risk (44%) patients, with annual HCC incidence rates of 6.2%, 1.8%, and 0.8%, respectively. High- and intermediate-risk groups were associated with sub-distribution hazard ratios for incident HCC of 6.54 (95% CI, 3.85-11.1) and 1.77 (95% CI, 1.02-3.08), respectively. Subgroup analysis showed robust risk stratification across HCC etiologies, including metabolic dysfunction-associated steatotic liver disease and cured hepatitis C infection. CONCLUSIONS: PAaM enables accurate HCC risk stratification in patients with cirrhosis from contemporary etiologies.
引用
- Fujiwara N, Lopez C, Marsh TL, et al. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2024. PMID: 39521255. doi:10.1053/j.gastro.2024.10.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。